文献速递神经核医学

淀粉样蛋白与Tau PET更新版适用标准:阿尔茨海默病协会与核医学与分子影像学会工作组报告

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
PubMed 文献 · J Nucl Med · 2025-06-06

阿尔茨海默病协会与核医学与分子影像学会召集多学科工作组,更新淀粉样蛋白PET适用标准并制定Tau PET适用标准。工作组基于系统文献综述建立17个临床场景,采用改良Delphi法分别对淀粉样蛋白PET和Tau PET独立评估。淀粉样蛋白PET有7个场景评为适用、2个不确定、8个罕见适用;Tau PET有5个适用、6个不确定、6个罕见适用。

要点

  • 淀粉样蛋白PET:7个场景适用、2个不确定、8个罕见适用。
  • Tau PET:5个场景适用、6个不确定、6个罕见适用。
  • 适用标准为淀粉样蛋白与Tau PET临床使用提供专家推荐。

核心结论

  • 淀粉样蛋白与Tau PET的适用标准为这些技术在阿尔茨海默病诊断和治疗演变格局中的临床使用提供专家推荐。

研究设计与样本

  • 阿尔茨海默病协会与核医学与分子影像学会召集多学科工作组,更新淀粉样蛋白PET适用标准并制定Tau PET适用标准。
  • 工作组确定关键研究问题,指导针对临床淀粉样蛋白/Tau PET的系统文献综述。
  • 基于该综述,工作组建立17个可考虑使用淀粉样蛋白或Tau PET的临床场景。
  • 采用改良Delphi法通过共识将每个场景评为「罕见适用」「不确定」或「适用」。
  • 分别对淀粉样蛋白PET和Tau PET作为独立模态进行评级。

主要发现

  • 淀粉样蛋白PET:7个场景评为适用,2个评为不确定,8个评为罕见适用。
  • Tau PET:5个场景评为适用,6个评为不确定,6个评为罕见适用。

关键数值与推荐

  • 淀粉样蛋白PET适用场景7个、不确定场景2个、罕见适用场景8个。
  • Tau PET适用场景5个、不确定场景6个、罕见适用场景6个。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as "rarely appropriate," "uncertain," or "appropriate." Ratings were performed separately for amyloid and tau PET as stand-alone modalities. Results: For amyloid PET, 7 scenarios were rated as appropriate, 2 as uncertain, and 8 as rarely appropriate. For tau PET, 5 scenarios were rated as appropriate, 6 as uncertain, and 6 as rarely appropriate. Conclusion: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rabinovici GD, Knopman DS, Arbizu J, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. J Nucl Med. 2025. PMID: 39778970. doi:10.2967/jnumed.124.268756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。